Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1964 3
1965 1
1966 2
1967 1
1968 1
1970 1
1971 1
1973 1
1974 1
1975 1
1977 1
1979 1
1980 1
1981 2
1982 2
1983 1
1984 3
1985 2
1986 5
1987 8
1989 6
1990 1
1991 6
1992 5
1993 6
1994 5
1995 8
1996 8
1997 7
1998 12
1999 10
2000 8
2001 17
2002 15
2003 17
2004 19
2005 24
2006 23
2007 17
2008 18
2009 30
2010 28
2011 28
2012 32
2013 33
2014 29
2015 44
2016 31
2017 24
2018 41
2019 43
2020 55
2021 42
2022 45
2023 24
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Results by year

Filters applied: . Clear all
Page 1
Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E. Jacobsen E. Am J Hematol. 2022 Dec;97(12):1638-1651. doi: 10.1002/ajh.26737. Epub 2022 Oct 18. Am J Hematol. 2022. PMID: 36255040 Free article.
DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. ...The overwhelming majority of cases have the characteristic t(14;18) translocation involving the IgH/bcl-2 gene …
DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed foll …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Hayden PJ, et al. Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34923107 Free article.
BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Pro …
BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved i …
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E. Freedman A, et al. Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814159 Free article. Review.
DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splen …
DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed foll …
Follicular lymphoma: an update on diagnosis, prognosis, and management.
Mozas P, Sorigué M, López-Guillermo A. Mozas P, et al. Med Clin (Barc). 2021 Nov 12;157(9):440-448. doi: 10.1016/j.medcli.2021.03.041. Epub 2021 Jun 29. Med Clin (Barc). 2021. PMID: 34210513 Review. English, Spanish.
Follicular lymphoma, the most common indolent lymphoma, originates from germinal centre B-cells of the lymphoid follicle, and is characterized by t(14;18). ...Although overall survival for most patients is prolonged, relapses are very frequent, and early rela …
Follicular lymphoma, the most common indolent lymphoma, originates from germinal centre B-cells of the lymphoid follicl …
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Dreyling M, et al. Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26. Ann Oncol. 2021. PMID: 33249059 Free article. No abstract available.
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Batlevi CL, et al. Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z. Blood Cancer J. 2020. PMID: 32678074 Free PMC article.
Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival based on lines of treatment remains poorly described in the post-rituximab era. Also, the Follicular Lymphoma International Pro …
Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival b …
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Casulo C, et al. Lancet Haematol. 2022 Apr;9(4):e289-e300. doi: 10.1016/S2352-3026(22)00033-3. Lancet Haematol. 2022. PMID: 35358443 Free PMC article.
BACKGROUND: Novel therapies for relapsed or refractory follicular lymphoma are commonly evaluated in single-arm studies without formal comparison with other treatments or historical controls. ...For this analysis, eligible patients were aged at least 18 years …
BACKGROUND: Novel therapies for relapsed or refractory follicular lymphoma are commonly evaluated in single-arm studies …
High-risk follicular lymphoma: Treatment options.
Kahl B. Kahl B. Hematol Oncol. 2021 Jun;39 Suppl 1:94-99. doi: 10.1002/hon.2853. Hematol Oncol. 2021. PMID: 34105813 Review.
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. ...However, several unmet needs remain, including a better ability to identify high-risk patients at diagnosis, the development of predictive biomarkers for t …
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. ...However, severa …
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T. van der Horst HJ, et al. Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. Blood Cancer J. 2021. PMID: 33602901 Free PMC article.
Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. ...These results show the promise of epcoritamab for treatment of newly-diagnosed or …
Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), …
Treatment of Histologic Transformation.
Casulo C. Casulo C. Hematol Oncol Clin North Am. 2020 Aug;34(4):785-794. doi: 10.1016/j.hoc.2020.03.001. Epub 2020 May 5. Hematol Oncol Clin North Am. 2020. PMID: 32586581 Review.
Histologic transformation from follicular lymphoma to aggressive lymphoma historically had a poor prognosis. Routine use of anti-CD20 antibody rituximab has changed the landscape of follicular lymphoma (FL) such that outcomes are improved in sel …
Histologic transformation from follicular lymphoma to aggressive lymphoma historically had a poor prognosis. Routine us …
735 results